Cancer of unknown primary site
Conditions
Interventions
carboplatin AUC5, 60 min div day1 TS-1 80mg/m2, twice daily day1-14 until 6 cycles without progression
Sponsors
National Cancer Center Hospital
Tochigi Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: a) pathologically diagnosed cancer of unknown primary site b) age over 20 years old c) Performance status (ECOG) 0-2 d) evaluable lesion based on RECIST e) met these criteria within 14 days before registration WBC >=3,000/mm3 or Neutrophil count >=1,500/mm3 hemoglobin >=9.0g/dL Platelet count >=10x104/mm3 T-bil <= 2.0mg/dl AST or ALT <=100IU/L serum Cre <=1.5mg/dL or CCr >=60ml/min(Cockcroft-Gault) f) No prior chemotherapy history g) Informed Consent from patient
Exclusion criteria
Exclusion criteria: a) favorable subset of CUP b) double cancer c) uncontrollable effusion in pleural or abdominal d) uncontrollable brain metastasis e)sever coexisting illness uncontrollable angina, AMI or congestive heart failure within 3 months, uncontrollable diabetes melitus active infection interstitial pneumonitis in CXR severe psychological problems uncontrollable diarrhea physician assessed the patient as ineligible the patients have to continue flucitocin, phenytoin and warfarin pregnant patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse event, survival outcome(OS, PFS) | — |
Countries
Japan
Contacts
Public ContactEmi Noguchi
National Cancer Center Hospital Department of Breast and Medical Oncology
Outcome results
None listed